Inflammatix
$57.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Inflammatix is currently valued at N/A as of September 12, 2024. The company has raised a total of $213.5M in funding.
Investment Perspective
Inflammatix's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Inflammatix Worth in 2025?
As of 2025, Inflammatix is valued at N/A, based on the company's Later Stage VC funding round in September 12, 2024. This valuation positions Inflammatix as one of the leading private companies in the sector.
Inflammatix Valuation History
Inflammatix's funding history demonstrates steady growth and investor confidence.
How Inflammatix Valuation is Determined
Private company valuations like Inflammatix's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Inflammatix Valuation FAQs
Is Inflammatix profitable?
Inflammatix has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Inflammatix's valuation compare to competitors?
Inflammatix is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Inflammatix IPO?
Inflammatix has not announced plans for an initial public offering. Until an IPO, investors can access Inflammatix shares through secondary market platforms.